Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q1 2021 · 10-Q
Revenue$4.36M$4.36M−38.4% vs Q1 2020 Net Income-$15.76M-$15.76MN/M vs Q1 2020 EPS Diluted-$0.42-$0.42N/M vs Q1 2020 Operating Income-$16,059,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$21,112,000N/M Margins · derivedOperating margin-368.5%−255.0 pt vs Q1 2020
Net margin-361.7%−256.0 pt vs Q1 2020
ended Mar 31, 2021 · filed May 11, 2021 · 41 d after period end